Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iin Narwanti

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Apoptosis : an International Journal on Programmed Cell Death|October 12, 2024
Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancerBidyadhar Sethy, Richa Upadhyay, Iin Narwanti, et al.
Bioorganic Chemistry|September 19, 2024
Design, synthesis, and biological evaluation of adenosine derivatives targeting DOT1L and HAT as anti-leukemia agentsBidyadhar Sethy, Zih-Yao Yu, Iin Narwanti, et al.
European Journal of Medicinal Chemistry|October 4, 2025
Quinoline-5,8-dione CDC25 inhibitors: Potent anti-cancer agents in leukemia and patient-derived colorectal organoidsIin Narwanti, Zih-Yao Yu, Bidyadhar Sethy, et al.
European Journal of Medicinal Chemistry|June 11, 2023
6-Regioisomeric 5,8-quinolinediones as potent CDC25 inhibitors against colorectal cancersIin Narwanti, Zih-Yao Yu, Bidyadhar Sethy, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 21, 2025
A novel quinoid-based CDC25 phosphatase inhibitor against human lung adenocarcinoma across different modelsTsung-Ching Lai, Iin Narwanti, Bidyadhar Sethy, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 26, 2025
A novel dual CDC25-HDAC inhibitor suppresses glioblastoma progression via chromosomal passenger complex disruptionRicha Upadhyay, Bidyadhar Sethy, Wen-Bin Yang, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Apoptosis : an International Journal on Programmed Cell Death|October 12, 2024
Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancerBidyadhar Sethy, Richa Upadhyay, Iin Narwanti, et al.
Bioorganic Chemistry|September 19, 2024
Design, synthesis, and biological evaluation of adenosine derivatives targeting DOT1L and HAT as anti-leukemia agentsBidyadhar Sethy, Zih-Yao Yu, Iin Narwanti, et al.
European Journal of Medicinal Chemistry|October 4, 2025
Quinoline-5,8-dione CDC25 inhibitors: Potent anti-cancer agents in leukemia and patient-derived colorectal organoidsIin Narwanti, Zih-Yao Yu, Bidyadhar Sethy, et al.
European Journal of Medicinal Chemistry|June 11, 2023
6-Regioisomeric 5,8-quinolinediones as potent CDC25 inhibitors against colorectal cancersIin Narwanti, Zih-Yao Yu, Bidyadhar Sethy, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 21, 2025
A novel quinoid-based CDC25 phosphatase inhibitor against human lung adenocarcinoma across different modelsTsung-Ching Lai, Iin Narwanti, Bidyadhar Sethy, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 26, 2025
A novel dual CDC25-HDAC inhibitor suppresses glioblastoma progression via chromosomal passenger complex disruptionRicha Upadhyay, Bidyadhar Sethy, Wen-Bin Yang, et al.
Pageof 1